Transthyretin Amyloidosis Treatment Market | USD 28.06 Billion by 2034
The transthyretin amyloidosis treatment market size was exhibited at USD 7.57 billion in 2024 and is projected to hit around USD 28.06 billion by 2034, growing at a CAGR of 14.0% during the forecast period 2025 to 2034.
The U.S. transthyretin amyloidosis treatment market size is evaluated at USD 2.73 billion in 2024 and is projected to be worth around USD 10.1 billion by 2034, growing at a CAGR of 12.62% from 2025 to 2034.
North America transthyretin amyloidosis treatment market dominated the global market with a revenue share of 47.8% in 2024. Increased awareness, favorable reimbursement policies, and innovative therapies encourage patient treatment-seeking behavior. Collaborations between pharmaceutical companies and research institutions are driving innovation, enhancing patient outcomes, and reinforcing North America's competitive advantage in the global market.
U.S. Transthyretin Amyloidosis Treatment Market Trends
The transthyretin amyloidosis treatment market in the U.S. dominated North America with the largest revenue share in 2024. Leading pharmaceutical companies facilitate rapid drug approvals and innovative treatment options. In addition, patient assistance programs improve therapy accessibility, while heightened awareness among healthcare professionals results in more timely diagnoses and interventions.
Europe Transthyretin Amyloidosis Treatment Market Trends
Europe transthyretin amyloidosis treatment market held substantial market share in 2024. Countries such as Germany and France are investing in healthcare infrastructure to improve access to specialized treatments. Ongoing clinical trials and research initiatives foster innovation, while collaboration between healthcare providers and pharmaceutical companies ensures timely and effective patient treatments.
The transthyretin amyloidosis treatment market in Germany is expected to grow in the forecast period. The country's advanced healthcare system enables access to cutting-edge therapies and clinical trials. Moreover, several key pharmaceutical companies contribute to developing transthyretin amyloidosis treatments, fostering innovation and availability. Increased healthcare professional awareness of disease symptoms promotes earlier diagnosis and treatment initiation, further propelling market growth.
Asia Pacific Transthyretin Amyloidosis Treatment Market Trends
Asia Pacific transthyretin amyloidosis treatment market is expected to register the fastest CAGR of 6.1% in the forecast period. Countries including Japan and Australia are advancing diagnostic capabilities and treatment options for transthyretin amyloidosis. The region's growing geriatric population contributes to higher disease incidence, driving demand for effective therapies. Collaborations between local healthcare providers and international pharmaceutical companies foster innovation and expand access to novel treatments.
The transthyretin amyloidosis treatment market in China dominated the Asia Pacific transthyretin amyloidosis treatment market in 2024. The Chinese government prioritizes health improvements, enhancing diagnostic and treatment access for transthyretin amyloidosis. Rising healthcare professional awareness facilitates earlier diagnoses and interventions, significantly increasing demand for effective therapies and positioning China as a key player in the region's market.
| Report Coverage | Details |
| Market Size in 2025 | USD 8.63 Billion |
| Market Size by 2034 | USD 28.06 Billion |
| Growth Rate From 2025 to 2034 | CAGR of 14.0% |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Segments Covered | Therapy, Type, Disease, Distribution Channel, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | Pfizer Inc.; Alnylam Pharmaceuticals, Inc.; Ionis Pharmaceuticals; AstraZeneca; Akcea Therapeutics; BridgeBio Inc.; Intellia Therapeutics, Inc.; SOM BIOTECH; Oncopeptides AB; Takeda Pharmaceutical Company Limited |
Targeted therapy dominated the market and accounted for a share of 86.9% in 2024, owing to the effectiveness of therapies such as tafamidis and patisiran, which directly address the disease's causes, enhance patient outcomes, and impede disease progression, fueling demand among healthcare providers.
Pipeline therapy is expected to grow lucratively over the forecast period, driven by advancements in drug development and clinical research. Investments by pharmaceutical companies in innovative treatments for both hereditary and wild-type forms are poised to yield new options. Current clinical trials focus on enhancing efficacy and minimizing side effects, further meeting the needs of underserved patient populations.
ATTR with Polyneuropathy (ATTR-PN) led the market with a revenue share of 79.3% in 2024, driven by its high prevalence and the significant neurological symptoms that necessitate effective management. Heightened awareness of this condition, coupled with advancements in treatment options, has led healthcare providers to prioritize therapies focused on polyneuropathy. Moreover, improved diagnostic capabilities enable earlier detection, facilitating timely interventions that yield better patient outcomes.
ATTR with Cardiomyopathy (ATTR-CM) is expected to grow at the fastest CAGR of 5.6% over the forecast period due to increasing awareness and improved diagnostic methods allowing for earlier identification of cardiomyopathy associated with transthyretin amyloidosis. As healthcare professionals enhance their understanding of the symptoms and implications of ATTR-CM, the demand for targeted therapies is anticipated to rise significantly.
Wild type amyloidosis held the largest market share of 55.1% in 2024, supported by greater recognition and diagnosis, particularly among older adults at higher risk. This demographic trend has resulted in an increased incidence, driving demand for effective treatment options. Furthermore, advancements in understanding the disease pathology and the emergence of targeted therapies have bolstered healthcare providers' confidence in managing wild type amyloidosis effectively.
Hereditary transthyretin amyloidosis is expected to register the fastest CAGR of 13.9% over the forecast period, propelled by the rise in genetic testing and awareness initiatives aimed at early identification of familial cases. An increasing number of diagnoses is generating demand for specialized treatments, while ongoing research into gene-silencing therapies further expands the treatment landscape and enhances market growth prospects.
Hospital pharmacies dominated the market and accounted for a share of 51.0% in 2024, attributed to their critical role in providing specialized medications and comprehensive care for patients with rare diseases, such as transthyretin amyloidosis. Their expertise in managing complex therapies ensures tailored treatment for patients. Moreover, hospital pharmacies often collaborate closely with healthcare providers to monitor patient outcomes and adjust treatment plans effectively.
Online pharmacies are projected to grow at the fastest CAGR of 14.7% over the forecast period. There has been a shift in consumer preferences toward convenience and accessibility for obtaining medications, particularly for chronic conditions such as transthyretin amyloidosis. The proliferation of telehealth services and digital health platforms enhances access to prescriptions, making online pharmacies increasingly attractive to patients seeking efficient healthcare solutions, including competitive pricing and home delivery options.
In November 2024, Alnylam Pharmaceuticals announced FDA acceptance of their supplemental New Drug Application for vutrisiran to treat ATTR amyloidosis with cardiomyopathy, with a PDUFA date set for March 23, 2025.
In October 2024, Wainzua (eplontersen) received a positive EU CHMP approval recommendation for treating hereditary transthyretin-mediated amyloidosis, demonstrating sustained benefits in neuropathy and quality of life versus placebo in Phase III trials.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the transthyretin amyloidosis treatment market
By Therapy
By Type
By Disease
By Distribution Channel
By Regional
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Therapy
1.2.2. Type
1.2.3. Disease
1.2.4. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Transthyretin Amyloidosis Treatment Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Transthyretin Amyloidosis Treatment Market: Therapy Business Analysis
4.1. Therapy Market Share, 2024 & 2034
4.2. Therapy Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2021 to 2034 (USD Million)
4.4. Targeted Therapy
4.4.1. Targeted Therapy Market, 2021 - 2034 (USD Million)
4.4.2. Vyndaqel/ Vyndamax
4.4.2.1. Vyndaqel/ Vyndamax Market, 2021 - 2034 (USD Million)
4.4.3. Onpattro
4.4.3.1. Onpattro Market, 2021 - 2034 (USD Million)
4.4.4. Amvuttra
4.4.4.1. Amvuttra Market, 2021 - 2034 (USD Million)
4.4.5. Tegsedi
4.4.5.1. Tegsedi Market, 2021 - 2034 (USD Million)
4.4.6. Wainua
4.4.6.1. Wainua Market, 2021 - 2034 (USD Million)
4.5. Supportive Therapy
4.5.1. Supportive Therapy Market, 2021 - 2034 (USD Million)
4.6. Pipeline Therapy
4.6.1. Pipeline Therapy Market, 2021 - 2034 (USD Million)
Chapter 5. Transthyretin Amyloidosis Treatment Market: Type Business Analysis
5.1. Type Market Share, 2024 & 2034
5.2. Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2034 (USD Million)
5.4. ATTR with Polyneuropathy (ATTR-PN)
5.4.1. ATTR with Polyneuropathy (ATTR-PN) Market, 2021 - 2034 (USD Million)
5.5. ATTR with Cardiomyopathy (ATTR-CM)
5.5.1. ATTR with Cardiomyopathy (ATTR-CM) Market, 2021 - 2034 (USD Million)
Chapter 6. Transthyretin Amyloidosis Treatment Market: Disease Business Analysis
6.1. Disease Market Share, 2024 & 2034
6.2. Disease Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2034 (USD Million)
6.4. Hereditary Transthyretin Amyloidosis
6.4.1. Hereditary Transthyretin Amyloidosis Market, 2021 - 2034 (USD Million)
6.4.2. Polyneuropathy
6.4.2.1. Polyneuropathy Market, 2021 - 2034 (USD Million)
6.4.3. Cardiomyopathy
6.4.3.1. Cardiomyopathy Market, 2021 - 2034 (USD Million)
6.4.4. Mixed Type
6.4.4.1. Mixed Type Market, 2021 - 2034 (USD Million)
6.5. Wild Type Amyloidosis
6.5.1. Wild Type Amyloidosis Market, 2021 - 2034 (USD Million)
Chapter 7. Transthyretin Amyloidosis Treatment Market: Distribution Channel Business Analysis
7.1. Distribution Channel Market Share, 2024 & 2034
7.2. Distribution Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2034 (USD Million)
7.4. Hospital Pharmacies
7.4.1. Hospital Pharmacies Market, 2021 - 2034 (USD Million)
7.5. Specialty Pharmacies
7.5.1. Specialty Pharmacies Market, 2021 - 2034 (USD Million)
7.6. Retail Pharmacies
7.6.1. Retail Pharmacies Market, 2021 - 2034 (USD Million)
7.7. Online Pharmacies
7.7.1. Online Pharmacies Market, 2021 - 2034 (USD Million)
Chapter 8. Transthyretin Amyloidosis Treatment Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2034
8.2. Regional Market Dashboard
8.3. Market Size, & Forecasts Trend Analysis, 2021 to 2034:
8.4. North America
8.4.1. North America Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2021 - 2034 (USD Million)
8.4.2. U.S.
8.4.2.1. Key Country Dynamics
8.4.2.2. Regulatory Framework
8.4.2.3. Competitive Insights
8.4.2.4. U.S. Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
8.4.3. Canada
8.4.3.1. Key Country Dynamics
8.4.3.2. Regulatory Framework
8.4.3.3. Competitive Insights
8.4.3.4. Canada Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
8.4.4. Mexico
8.4.4.1. Key Country Dynamics
8.4.4.2. Regulatory Framework
8.4.4.3. Competitive Insights
8.4.4.4. Mexico Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
8.5. Europe
8.5.1. Europe Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2021 - 2034 (USD Million)
8.5.2. UK
8.5.2.1. Key Country Dynamics
8.5.2.2. Regulatory Framework
8.5.2.3. Competitive Insights
8.5.2.4. UK Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
8.5.3. Germany
8.5.3.1. Key Country Dynamics
8.5.3.2. Regulatory Framework
8.5.3.3. Competitive Insights
8.5.3.4. Germany Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
8.5.4. France
8.5.4.1. Key Country Dynamics
8.5.4.2. Regulatory Framework
8.5.4.3. Competitive Insights
8.5.4.4. France Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
8.5.5. Italy
8.5.5.1. Key Country Dynamics
8.5.5.2. Regulatory Framework
8.5.5.3. Competitive Insights
8.5.5.4. Italy Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
8.5.6. Spain
8.5.6.1. Key Country Dynamics
8.5.6.2. Regulatory Framework
8.5.6.3. Competitive Insights
8.5.6.4. Spain Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
8.5.7. Norway
8.5.7.1. Key Country Dynamics
8.5.7.2. Regulatory Framework
8.5.7.3. Competitive Insights
8.5.7.4. Norway Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
8.5.8. Denmark
8.5.8.1. Key Country Dynamics
8.5.8.2. Regulatory Framework
8.5.8.3. Competitive Insights
8.5.8.4. Denmark Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
8.5.9. Sweden
8.5.9.1. Key Country Dynamics
8.5.9.2. Regulatory Framework
8.5.9.3. Competitive Insights
8.5.9.4. Sweden Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2021 - 2034 (USD Million)
8.6.2. Japan
8.6.2.1. Key Country Dynamics
8.6.2.2. Regulatory Framework
8.6.2.3. Competitive Insights
8.6.2.4. Japan Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
8.6.3. China
8.6.3.1. Key Country Dynamics
8.6.3.2. Regulatory Framework
8.6.3.3. Competitive Insights
8.6.3.4. China Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
8.6.4. India
8.6.4.1. Key Country Dynamics
8.6.4.2. Regulatory Framework
8.6.4.3. Competitive Insights
8.6.4.4. India Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
8.6.5. South Korea
8.6.5.1. Key Country Dynamics
8.6.5.2. Regulatory Framework
8.6.5.3. Competitive Insights
8.6.5.4. South Korea Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
8.6.6. Australia
8.6.6.1. Key Country Dynamics
8.6.6.2. Regulatory Framework
8.6.6.3. Competitive Insights
8.6.6.4. Australia Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
8.6.7. Thailand
8.6.7.1. Key Country Dynamics
8.6.7.2. Regulatory Framework
8.6.7.3. Competitive Insights
8.6.7.4. Thailand Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
8.7. Latin America
8.7.1. Latin America Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2021 - 2034 (USD Million)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. Regulatory Framework
8.7.2.3. Competitive Insights
8.7.2.4. Brazil Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. Regulatory Framework
8.7.3.3. Competitive Insights
8.7.3.4. Argentina Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
8.8. MEA
8.8.1. MEA Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2021 - 2034 (USD Million)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. Regulatory Framework
8.8.2.3. Competitive Insights
8.8.2.4. South Africa Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. Regulatory Framework
8.8.3.3. Competitive Insights
8.8.3.4. Saudi Arabia Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. Regulatory Framework
8.8.4.3. Competitive Insights
8.8.4.4. UAE Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. Regulatory Framework
8.8.5.3. Competitive Insights
8.8.5.4. Kuwait Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2021 - 2034 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. Pfizer Inc.
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. Alnylam Pharmaceuticals, Inc.
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. Ionis Pharmaceuticals
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. AstraZeneca
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. Akcea Therapeutics
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. BridgeBio Inc.
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. Intellia Therapeutics, Inc.
9.5.7.1. Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. SOM BIOTECH
9.5.8.1. Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives
9.5.9. Oncopeptides AB
9.5.9.1. Overview
9.5.9.2. Financial Performance
9.5.9.3. Product Benchmarking
9.5.9.4. Strategic Initiatives
9.5.10. Takeda Pharmaceutical Company Limited
9.5.10.1. Overview
9.5.10.2. Financial Performance
9.5.10.3. Product Benchmarking
9.5.10.4. Strategic Initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers